- Target enrollment milestone reached in the Phase 3 EMERALD study - Life cycle planning advancing in parallel with current Phase 3 monotherapy program Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial. EMERALD Phase 3 Study The target enrollment milestone has been reached in the Phase 3 EMERALD clinical trial of elacestrant. Elacestrant is an oral Selective Estrogen Receptor Degrader (SERD)